Investigational drug · Phase 3
IHL-42X
Also called: Investigational Product - IHL-42X, Optimal Dose
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Obstructive Sleep Apnea.
Phase 3Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "IHL-42X"
First trial start
2024
May 2, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IHL-42X", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obstructive Sleep Apnea
Largest trials
Live from ClinicalTrials.gov: studies naming "IHL-42X" as an intervention, largest first.
- Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference DrugsPivotal-lookingCompleted
Incannex Healthcare LtdIndustry
NCT05857384 · 125 participants · Start Sep 8, 2023 · Primary completion Jul 31, 2024
Drug: IHL42X; Acetazolamide 250 MG and 1 more · For: Obstructive Sleep Apnea
Sites: Adelaide, Australia; Geelong, Australia; Melbourne, Australia · 4 sites in all
- RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSAPivotal-lookingCompleted
Incannex Healthcare LtdIndustry
NCT06146101 · 121 participants · Start May 2, 2024 · Primary completion May 20, 2025
Drug: IHL-42X Low Dose; IHL-42X High Dose and 5 more · For: Obstructive Sleep Apnea
Sites: Chula Vista, California; Long Beach, California; Upland, California · 20 sites in all
- DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.Pivotal-lookingRecruiting
Incannex Healthcare LtdIndustry
NCT07635563 · 120 participants (planned) · Start Jul 21, 2026 · Primary completion Apr 2027
Drug: IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide; IHL-42X: 5 mg dronabinol + 125 mg acetazolamide and 8 more · For: Obstructive Sleep Apnea (OSA)
Sites: Chula Vista, California; Brandon, Florida; Jacksonville, Florida · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Optimal dose window, formulation efficacy, and molecular mechanisms of curcumin in MASLD animal models: A systematic review and three-level meta-analysis.
Zhang C, Fu G, Zhang Y, et al. · J Ethnopharmacol 2027
- Natural products alleviate exercise-induced fatigue by modulating gut microbiota: a systematic review.
Yan D, Jiao T · J Int Soc Sports Nutr 2026
- Roadmap for cognitive neurorehabilitation: challenges and opportunities.
Sokolov AA, Allain P, d'Honincthun P, et al. · Curr Opin Neurol 2026
- Effect of intranasal insulin on postoperative delirium: A systematic review and dose-response meta-analysis.
Saeed O, Nounou MV, Saeed A, et al. · Crit Care Resusc 2026
- A Brown Norway rat sensitisation model can rank foods according to their allergenicity in humans.
Shafie B, Sancho AI, Looi AD, et al. · Food Res Int 2026
- Influence of dietary protein deficiency on the progression and resolution of CClࠤ-induced liver damage.
D'Souza V, Augustin V, Rj M, et al. · Toxicol Appl Pharmacol 2026
Also in development for Obstructive Sleep Apnea
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- lorundrostatPhase 35 trials
Mineralys Therapeutics Inc. · Hypertension, Obstructive Sleep Apnea, Chronic Kidney Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.